Cargando…

Molecular markers associated with outcome and metastasis in human pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous cancer in which differences in survival rates might be related to a variety in gene expression profiles. Although the molecular biology of PDAC begins to be revealed, genes or pathways that specifically drive tumour progression o...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Broeck, Anke, Vankelecom, Hugo, Van Eijsden, Rudy, Govaere, Olivier, Topal, Baki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511800/
https://www.ncbi.nlm.nih.gov/pubmed/22925330
http://dx.doi.org/10.1186/1756-9966-31-68
_version_ 1782251652365942784
author Van den Broeck, Anke
Vankelecom, Hugo
Van Eijsden, Rudy
Govaere, Olivier
Topal, Baki
author_facet Van den Broeck, Anke
Vankelecom, Hugo
Van Eijsden, Rudy
Govaere, Olivier
Topal, Baki
author_sort Van den Broeck, Anke
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous cancer in which differences in survival rates might be related to a variety in gene expression profiles. Although the molecular biology of PDAC begins to be revealed, genes or pathways that specifically drive tumour progression or metastasis are not well understood. METHODS: We performed microarray analyses on whole-tumour samples of 2 human PDAC subpopulations with similar clinicopathological features, but extremely distinct survival rates after potentially curative surgery, i.e. good outcome (OS and DFS > 50 months, n = 7) versus bad outcome (OS < 19 months and DFS < 7 months, n = 10). Additionally, liver- and peritoneal metastases were analysed and compared to primary cancer tissue (n = 11). RESULTS: The integrin and ephrin receptor families were upregulated in all PDAC samples, irrespective of outcome, supporting an important role of the interaction between pancreatic cancer cells and the surrounding desmoplastic reaction in tumorigenesis and cancer progression. Moreover, some components such as ITGB1 and EPHA2 were upregulated in PDAC samples with a poor outcome, Additionally, overexpression of the non-canonical Wnt/β-catenin pathway and EMT genes in PDAC samples with bad versus good outcome suggests their contribution to the invasiveness of pancreatic cancer, with β-catenin being also highly upregulated in metastatic tissue. CONCLUSIONS: Components of the integrin and ephrin pathways and EMT related genes, might serve as molecular markers in pancreatic cancer as their expression seems to be related with prognosis.
format Online
Article
Text
id pubmed-3511800
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35118002012-12-02 Molecular markers associated with outcome and metastasis in human pancreatic cancer Van den Broeck, Anke Vankelecom, Hugo Van Eijsden, Rudy Govaere, Olivier Topal, Baki J Exp Clin Cancer Res Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous cancer in which differences in survival rates might be related to a variety in gene expression profiles. Although the molecular biology of PDAC begins to be revealed, genes or pathways that specifically drive tumour progression or metastasis are not well understood. METHODS: We performed microarray analyses on whole-tumour samples of 2 human PDAC subpopulations with similar clinicopathological features, but extremely distinct survival rates after potentially curative surgery, i.e. good outcome (OS and DFS > 50 months, n = 7) versus bad outcome (OS < 19 months and DFS < 7 months, n = 10). Additionally, liver- and peritoneal metastases were analysed and compared to primary cancer tissue (n = 11). RESULTS: The integrin and ephrin receptor families were upregulated in all PDAC samples, irrespective of outcome, supporting an important role of the interaction between pancreatic cancer cells and the surrounding desmoplastic reaction in tumorigenesis and cancer progression. Moreover, some components such as ITGB1 and EPHA2 were upregulated in PDAC samples with a poor outcome, Additionally, overexpression of the non-canonical Wnt/β-catenin pathway and EMT genes in PDAC samples with bad versus good outcome suggests their contribution to the invasiveness of pancreatic cancer, with β-catenin being also highly upregulated in metastatic tissue. CONCLUSIONS: Components of the integrin and ephrin pathways and EMT related genes, might serve as molecular markers in pancreatic cancer as their expression seems to be related with prognosis. BioMed Central 2012-08-27 /pmc/articles/PMC3511800/ /pubmed/22925330 http://dx.doi.org/10.1186/1756-9966-31-68 Text en Copyright ©2012 Van den Broeck et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Van den Broeck, Anke
Vankelecom, Hugo
Van Eijsden, Rudy
Govaere, Olivier
Topal, Baki
Molecular markers associated with outcome and metastasis in human pancreatic cancer
title Molecular markers associated with outcome and metastasis in human pancreatic cancer
title_full Molecular markers associated with outcome and metastasis in human pancreatic cancer
title_fullStr Molecular markers associated with outcome and metastasis in human pancreatic cancer
title_full_unstemmed Molecular markers associated with outcome and metastasis in human pancreatic cancer
title_short Molecular markers associated with outcome and metastasis in human pancreatic cancer
title_sort molecular markers associated with outcome and metastasis in human pancreatic cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511800/
https://www.ncbi.nlm.nih.gov/pubmed/22925330
http://dx.doi.org/10.1186/1756-9966-31-68
work_keys_str_mv AT vandenbroeckanke molecularmarkersassociatedwithoutcomeandmetastasisinhumanpancreaticcancer
AT vankelecomhugo molecularmarkersassociatedwithoutcomeandmetastasisinhumanpancreaticcancer
AT vaneijsdenrudy molecularmarkersassociatedwithoutcomeandmetastasisinhumanpancreaticcancer
AT govaereolivier molecularmarkersassociatedwithoutcomeandmetastasisinhumanpancreaticcancer
AT topalbaki molecularmarkersassociatedwithoutcomeandmetastasisinhumanpancreaticcancer